Published in J Neuroinflammation on June 21, 2012
Inflammation in neurodegenerative diseases--an update. Immunology (2014) 1.30
The alternative complement pathway propagates inflammation and injury in murine ischemic stroke. J Immunol (2012) 1.03
Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis. Front Cell Neurosci (2014) 1.01
MicroRNA dysregulation in spinal cord injury: causes, consequences and therapeutics. Front Cell Neurosci (2014) 0.91
The Immune Response to Acute Focal Cerebral Ischemia and Associated Post-stroke Immunodepression: A Focused Review. Aging Dis (2014) 0.90
Complement-triggered pathways orchestrate regenerative responses throughout phylogenesis. Semin Immunol (2013) 0.89
Using genetic mouse models to gain insight into glaucoma: Past results and future possibilities. Exp Eye Res (2015) 0.88
Complement component 3 is necessary to preserve myocardium and myocardial function in chronic myocardial infarction. Stem Cells (2014) 0.86
Genome-wide gene expression profiling of stress response in a spinal cord clip compression injury model. BMC Genomics (2013) 0.86
The role of the immune system in central nervous system plasticity after acute injury. Neuroscience (2014) 0.84
CD11d Antibody Treatment Improves Recovery in Spinal Cord-Injured Mice. J Neurotrauma (2011) 0.82
Deficiency of complement receptors CR2/CR1 in Cr2⁻/⁻ mice reduces the extent of secondary brain damage after closed head injury. J Neuroinflammation (2014) 0.80
Synthesis and propagation of complement C3 by microglia/monocytes in the aging retina. PLoS One (2014) 0.80
Complement activation fragment C5a receptors, CD88 and C5L2, are associated with neurofibrillary pathology. J Neuroinflammation (2013) 0.79
Inflammogenesis of Secondary Spinal Cord Injury. Front Cell Neurosci (2016) 0.78
Protective effects of decay-accelerating factor on blast-induced neurotrauma in rats. Acta Neuropathol Commun (2013) 0.78
Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer's disease. J Neuroinflammation (2015) 0.77
The Complement System Component C5a Produces Thermal Hyperalgesia via Macrophage-to-Nociceptor Signaling That Requires NGF and TRPV1. J Neurosci (2016) 0.77
Delayed post-injury administration of C5a improves regeneration and functional recovery after spinal cord injury in mice. Clin Exp Immunol (2013) 0.77
Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement. J Neuroinflammation (2015) 0.77
IVIg attenuates complement and improves spinal cord injury outcomes in mice. Ann Clin Transl Neurol (2016) 0.77
Treatment of spinal cord injury with intravenous immunoglobulin G: preliminary evidence and future perspectives. J Clin Immunol (2014) 0.76
Complement system activation contributes to the ependymal damage induced by microbial neuraminidase. J Neuroinflammation (2016) 0.76
Impaired Pituitary Axes Following Traumatic Brain Injury. J Clin Med (2015) 0.76
Mild hypothermia inhibits systemic and cerebral complement activation in a swine model of cardiac arrest. J Cereb Blood Flow Metab (2015) 0.75
Ganglioside deficiency causes inflammation and neurodegeneration via the activation of complement system in the spinal cord. J Neuroinflammation (2014) 0.75
Systemic Administration of Induced Neural Stem Cells Regulates Complement Activation in Mouse Closed Head Injury Models. Sci Rep (2017) 0.75
Pharmacological inhibition of mannose-binding lectin ameliorates neurobehavioral dysfunction following experimental traumatic brain injury. J Cereb Blood Flow Metab (2016) 0.75
Complement component C3a plays a critical role in endothelial activation and leukocyte recruitment into the brain. J Neuroinflammation (2016) 0.75
Transcriptomic evidence of a para-inflammatory state in the middle aged lumbar spinal cord. Immun Ageing (2017) 0.75
Low serum ficolin-3 levels are associated with severity and poor outcome in traumatic brain injury. J Neuroinflammation (2015) 0.75
Dietary n-3 PUFAs Deficiency Increases Vulnerability to Inflammation-Induced Spatial Memory Impairment. Neuropsychopharmacology (2015) 0.75
DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol (2006) 10.73
Complement: a key system for immune surveillance and homeostasis. Nat Immunol (2010) 10.37
The classical complement cascade mediates CNS synapse elimination. Cell (2007) 9.06
Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci (2009) 6.93
Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med (2006) 5.26
IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest (1998) 4.77
The complement system in regulation of adaptive immunity. Nat Immunol (2004) 4.58
Interleukin-6 family of cytokines and gp130. Blood (1995) 4.52
Human C'3: evidence for the liver as the primary site of synthesis. Science (1969) 4.17
Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med (2009) 3.68
Functional roles for C5a receptors in sepsis. Nat Med (2008) 3.33
The chemotactic receptor for human C5a anaphylatoxin. Nature (1991) 3.15
Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med (1981) 2.88
Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury. Exp Neurol (1999) 2.78
The mannose receptor is a pattern recognition receptor involved in host defense. Curr Opin Immunol (1998) 2.31
Structural and functional composition of the developing retinogeniculate pathway in the mouse. Vis Neurosci (2005) 2.15
Acute spinal cord injury, part I: pathophysiologic mechanisms. Clin Neuropharmacol (2001) 2.14
Post-traumatic inflammation following spinal cord injury. Spinal Cord (2003) 2.13
Molecular intercommunication between the complement and coagulation systems. J Immunol (2010) 2.12
The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med (2005) 2.09
C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature (2007) 2.06
Therapeutic potential of complement modulation. Nat Rev Drug Discov (2009) 1.85
Transient blockade of the CD11d/CD18 integrin reduces secondary damage after spinal cord injury, improving sensory, autonomic, and motor function. J Neurosci (2004) 1.80
The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74). J Biol Chem (2001) 1.80
Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci (2008) 1.78
The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J Biol Chem (2009) 1.73
C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proc Natl Acad Sci U S A (2012) 1.73
Inhibiting the C5-C5a receptor axis. Mol Immunol (2011) 1.73
Complement: a novel factor in basal and ischemia-induced neurogenesis. EMBO J (2006) 1.70
A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol (2008) 1.70
Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol (2009) 1.66
Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science (1999) 1.65
C1-inhibitor attenuates neurobehavioral deficits and reduces contusion volume after controlled cortical impact brain injury in mice. Crit Care Med (2009) 1.64
Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ Res (2006) 1.63
Structure and activation of the C1 complex of complement: unraveling the puzzle. Trends Immunol (2004) 1.59
Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology (2000) 1.56
The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol (2008) 1.52
Recovery of locomotion after spinal cord injury: some facts and mechanisms. Annu Rev Neurosci (2011) 1.49
The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration. J Neurochem (2008) 1.48
Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci U S A (2007) 1.46
Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease. J Neurochem (2008) 1.45
Role of neutrophils in spinal cord injury in the rat. Neuroscience (1997) 1.45
The human complement fragment receptor, C5L2, is a recycling decoy receptor. Mol Immunol (2008) 1.45
Complement protein C1q-mediated neuroprotection is correlated with regulation of neuronal gene and microRNA expression. J Neurosci (2011) 1.41
Complement in the brain. Mol Immunol (2011) 1.41
Enhanced synaptic connectivity and epilepsy in C1q knockout mice. Proc Natl Acad Sci U S A (2010) 1.38
B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice. J Clin Invest (2009) 1.37
Attenuation of experimental autoimmune demyelination in complement-deficient mice. J Immunol (2000) 1.37
Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke. PLoS One (2010) 1.35
Depletion of Ly6G/Gr-1 leukocytes after spinal cord injury in mice alters wound healing and worsens neurological outcome. J Neurosci (2009) 1.35
Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J (2006) 1.33
Recombinant C1 inhibitor in brain ischemic injury. Ann Neurol (2009) 1.33
Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. J Neuroimmunol (2004) 1.29
The role of the complement system and the activation fragment C5a in the central nervous system. Neuromolecular Med (2009) 1.27
Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. Am J Pathol (2000) 1.27
C1q: the perfect complement for a synaptic feast? Nat Rev Neurosci (2008) 1.26
Complement component 5a (C5a). Int J Biochem Cell Biol (2009) 1.24
Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice. J Neuroinflammation (2007) 1.24
Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis. FASEB J (2012) 1.21
Mouse strains with typical mammalian levels of complement activity. J Immunol Methods (1989) 1.21
Elevated levels of the complement components C3 and factor B in ventricular cerebrospinal fluid of patients with traumatic brain injury. J Neuroimmunol (1997) 1.19
Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J Cell Biochem (1999) 1.18
C3a receptor modulation of granulocyte infiltration after murine focal cerebral ischemia is reperfusion dependent. J Cereb Blood Flow Metab (2008) 1.18
Inhibition of monocyte/macrophage migration to a spinal cord injury site by an antibody to the integrin alphaD: a potential new anti-inflammatory treatment. Exp Neurol (2000) 1.18
Inflammatory signals induce neurotrophin expression in human microglial cells. J Neurochem (1998) 1.18
Activation of complement pathways after contusion-induced spinal cord injury. J Neurotrauma (2004) 1.17
Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am J Pathol (2006) 1.17
Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clin Exp Immunol (2008) 1.17
Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience (2008) 1.16
Neuroinflammation in Huntington's disease. J Neural Transm (Vienna) (2010) 1.16
Concept of autoimmunity following spinal cord injury: possible roles for T lymphocytes in the traumatized central nervous system. J Neurosci Res (1996) 1.14
Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury. Exp Neurol (2006) 1.14
Complement activation in the human brain after traumatic head injury. J Neurotrauma (2001) 1.13
Complement component c1q mediates mitochondria-driven oxidative stress in neonatal hypoxic-ischemic brain injury. J Neurosci (2010) 1.13
The powerful neuroprotective action of C1-inhibitor on brain ischemia-reperfusion injury does not require C1q. Am J Pathol (2004) 1.12
Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. Br J Pharmacol (2004) 1.11
Mouse complement component C4 is devoid of classical pathway C5 convertase subunit activity. Mol Immunol (1996) 1.11
Complement C1q is dramatically up-regulated in brain microglia in response to transient global cerebral ischemia. J Immunol (2000) 1.11
Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice. J Immunol (2011) 1.10
Reduced neuronal cell death after experimental brain injury in mice lacking a functional alternative pathway of complement activation. BMC Neurosci (2006) 1.09
The role of the complement system in traumatic brain injury. Brain Res Brain Res Rev (1998) 1.07
Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death. Neuroreport (2001) 1.06
Ficolins and the fibrinogen-like domain. Immunobiology (1998) 1.06
Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by inhibition of caspase-3 activation. J Immunol (1999) 1.06
Complement component C1q inhibits beta-amyloid- and serum amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. J Neurochem (2007) 1.06
Histological and direct evidence for the role of complement in the neuroinflammation of AD. Curr Alzheimer Res (2011) 1.05
Complement anaphylatoxin C5a neuroprotects through mitogen-activated protein kinase-dependent inhibition of caspase 3. J Neurochem (2001) 1.05
Complement in neuroprotection and neurodegeneration. Trends Mol Med (2010) 1.04
Expression of complement system components during aging and amyloid deposition in APP transgenic mice. J Neuroinflammation (2009) 1.04
C1-inhibitor protects against brain ischemia-reperfusion injury via inhibition of cell recruitment and inflammation. Neurobiol Dis (2005) 1.03
Role of complement anaphylatoxin receptors (C3aR, C5aR) in the development of the rat cerebellum. Mol Immunol (2008) 1.02
Complement anaphylatoxin C5a neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo. J Neuroinflammation (2008) 1.02
Intrathecal levels of complement-derived soluble membrane attack complex (sC5b-9) correlate with blood-brain barrier dysfunction in patients with traumatic brain injury. J Neurotrauma (2001) 1.01
Deficiency in complement C1q improves histological and functional locomotor outcome after spinal cord injury. J Neurosci (2008) 1.01
The C3a receptor antagonist SB 290157 has agonist activity. Immunol Lett (2005) 1.01
Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J Biol Chem (1996) 1.01
Alterations in plasma complement levels after human ischemic stroke. Neurosurgery (2006) 1.00
Absence of the complement regulatory molecule CD59a leads to exacerbated neuropathology after traumatic brain injury in mice. J Neuroinflammation (2009) 1.00
C5b-9 terminal complex protects oligodendrocytes from apoptotic cell death by inhibiting caspase-8 processing and up-regulating FLIP. J Immunol (2006) 0.99
Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J Neurotrauma (2006) 5.32
Human neural stem cells differentiate and promote locomotor recovery in spinal cord-injured mice. Proc Natl Acad Sci U S A (2005) 3.56
Toll-like receptors in ischemia-reperfusion injury. Shock (2009) 1.92
Human neural stem cells induce functional myelination in mice with severe dysmyelination. Sci Transl Med (2012) 1.82
The role of the complement system in ischemia-reperfusion injury. Shock (2004) 1.82
Human neural stem cells differentiate and promote locomotor recovery in an early chronic spinal cord injury NOD-scid mouse model. PLoS One (2010) 1.66
Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol (2009) 1.66
Mobilisation of the splenic monocyte reservoir and peripheral CX₃CR1 deficiency adversely affects recovery from spinal cord injury. Exp Neurol (2013) 1.60
Voluntary wheel running improves recovery from a moderate spinal cord injury. J Neurotrauma (2005) 1.60
The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol (2008) 1.52
Complement factor C5a as mast cell activator mediates vascular remodelling in vein graft disease. Cardiovasc Res (2012) 1.49
Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol Neurodegener (2011) 1.48
A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int (2003) 1.41
A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol (2003) 1.40
Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J (2006) 1.33
C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J (2012) 1.28
The role of the complement system and the activation fragment C5a in the central nervous system. Neuromolecular Med (2009) 1.27
Analysis of host-mediated repair mechanisms after human CNS-stem cell transplantation for spinal cord injury: correlation of engraftment with recovery. PLoS One (2009) 1.27
Polymorphonuclear leukocytes promote neurotoxicity through release of matrix metalloproteinases, reactive oxygen species, and TNF-alpha. J Neurochem (2007) 1.25
Complement component 5a (C5a). Int J Biochem Cell Biol (2009) 1.24
Dendritic cell function in allostimulation is modulated by C5aR signaling. J Immunol (2009) 1.24
Behavioral, histological, and ex vivo magnetic resonance imaging assessment of graded contusion spinal cord injury in mice. J Neurotrauma (2007) 1.24
The chemokine receptor CX3CR1 mediates homing of MHC class II-positive cells to the normal mouse corneal epithelium. Invest Ophthalmol Vis Sci (2007) 1.24
Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis. FASEB J (2012) 1.21
Microglia modulate hippocampal neural precursor activity in response to exercise and aging. J Neurosci (2012) 1.21
Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. J Neuroinflammation (2013) 1.21
The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization. Proc Natl Acad Sci U S A (2013) 1.21
Wheel running following spinal cord injury improves locomotor recovery and stimulates serotonergic fiber growth. Eur J Neurosci (2007) 1.20
Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer's disease. J Neurochem (2010) 1.16
Multifunctional, multichannel bridges that deliver neurotrophin encoding lentivirus for regeneration following spinal cord injury. Biomaterials (2011) 1.13
Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. Br J Pharmacol (2004) 1.11
Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation. J Immunol (2007) 1.10
Protective effects of a potent C5a receptor antagonist on experimental acute limb ischemia-reperfusion in rats. J Surg Res (2004) 1.09
Accumulation of murine subretinal macrophages: effects of age, pigmentation and CX3CR1. Neurobiol Aging (2011) 1.08
Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine. J Surg Res (2002) 1.08
Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist. Br J Pharmacol (2003) 1.05
Immature doublecortin-positive hippocampal neurons are important for learning but not for remembering. J Neurosci (2013) 1.04
De novo peptide design with C3a receptor agonist and antagonist activities: theoretical predictions and experimental validation. J Med Chem (2012) 1.04
Complement mediators in ischemia-reperfusion injury. Clin Chim Acta (2006) 1.03
Fas and Fas ligand are associated with neuritic degeneration in the AD brain and participate in beta-amyloid-induced neuronal death. Neurobiol Dis (2003) 1.03
Plasmid releasing multiple channel bridges for transgene expression after spinal cord injury. Mol Ther (2008) 1.03
Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum (2002) 1.03
Vertebral landmarks for the identification of spinal cord segments in the mouse. Neuroimage (2012) 1.02
Multiple channel bridges for spinal cord injury: cellular characterization of host response. Tissue Eng Part A (2009) 1.02
Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats. J Hepatol (2004) 1.01
Deficiency in complement C1q improves histological and functional locomotor outcome after spinal cord injury. J Neurosci (2008) 1.01
Complement C5a inhibition reduces atherosclerosis in ApoE-/- mice. FASEB J (2011) 1.00
Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity. Mol Pharmacol (2004) 1.00
Human neural stem cell differentiation following transplantation into spinal cord injured mice: association with recovery of locomotor function. Neurol Res (2006) 1.00
Eph/Ephrin signaling in injury and inflammation. Am J Pathol (2012) 1.00
Novel characterization of monocyte-derived cell populations in the meninges and choroid plexus and their rates of replenishment in bone marrow chimeric mice. J Neuropathol Exp Neurol (2010) 0.98
Immune cell trafficking from the brain maintains CNS immune tolerance. J Clin Invest (2014) 0.98
Viral vector-mediated gene transfer of neurotrophins to promote regeneration of the injured spinal cord. Prog Brain Res (2004) 0.97
Safety of human neural stem cell transplantation in chronic spinal cord injury. Stem Cells Transl Med (2013) 0.97
Profound differences in spontaneous long-term functional recovery after defined spinal tract lesions in the rat. J Neurotrauma (2006) 0.96
Optimization of techniques for the maximal detection and quantification of Alzheimer's-related neuropathology with digital imaging. Neurobiol Aging (2002) 0.95
Comparative agonist/antagonist responses in mutant human C5a receptors define the ligand binding site. J Biol Chem (2005) 0.95
The role of the N-terminal domain of the complement fragment receptor C5L2 in ligand binding. J Biol Chem (2006) 0.95
Antifibrotic activity of an inhibitor of group IIA secretory phospholipase A2 in young spontaneously hypertensive rats. J Immunol (2006) 0.95
Complement in pregnancy: a delicate balance. Am J Reprod Immunol (2012) 0.94
Characterization of early and terminal complement proteins associated with polymorphonuclear leukocytes in vitro and in vivo after spinal cord injury. J Neuroinflammation (2008) 0.93
The induction of the TNFalpha death domain signaling pathway in Alzheimer's disease brain. Neurochem Res (2003) 0.92
The role of complement in innate, adaptive and eosinophil-dependent immunity to the nematode Nippostrongylus brasiliensis. Mol Immunol (2007) 0.92
Longitudinal assessment of white matter pathology in the injured mouse spinal cord through ultra-high field (16.4 T) in vivo diffusion tensor imaging. Neuroimage (2013) 0.92
Quantitative assessment of immune cells in the injured spinal cord tissue by flow cytometry: a novel use for a cell purification method. J Vis Exp (2011) 0.92
Adaptation of a ladder beam walking task to assess locomotor recovery in mice following spinal cord injury. Behav Brain Res (2007) 0.91
Local and remote immune-mediated inflammation after mild peripheral nerve compression in rats. J Neuropathol Exp Neurol (2013) 0.90
Safety of epicenter versus intact parenchyma as a transplantation site for human neural stem cells for spinal cord injury therapy. Stem Cells Transl Med (2013) 0.90
A convergent solution-phase synthesis of the macrocycle Ac-Phe-[Orn-Pro-D-Cha-Trp-Arg], a potent new antiinflammatory drug. J Org Chem (2003) 0.90
Immunosuppressants affect human neural stem cells in vitro but not in an in vivo model of spinal cord injury. Stem Cells Transl Med (2013) 0.90
Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease. J Pharmacol Exp Ther (2005) 0.90
Complement inhibitors selectively attenuate injury following administration of cobra venom factor to rats. Int Immunopharmacol (2006) 0.89
Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br J Pharmacol (2002) 0.89
Evidence that adiponectin receptor 1 activation exacerbates ischemic neuronal death. Exp Transl Stroke Med (2010) 0.88
Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol (2011) 0.88
A potent and selective inhibitor of group IIa secretory phospholipase A2 protects rats from TNBS-induced colitis. Int Immunopharmacol (2005) 0.88
Channel density and porosity of degradable bridging scaffolds on axon growth after spinal injury. Biomaterials (2013) 0.87